Last reviewed · How we verify
APX005M
At a glance
| Generic name | APX005M |
|---|---|
| Also known as | CD40 Agonistic Monoclonal Antibody, PYX-107, Sotigalimab, APX-005M, CD40 |
| Sponsor | Apexigen America, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Fatigue
- Nausea
- Aspartate aminotransferase increased
- Constipation
- Diarrhoea
- Alanine aminotransferase increased
- Anaemia
- Decreased appetite
- Vomiting
- Pyrexia
- Thrombocytopenia
- Chills
Key clinical trials
- Switch Maintenance in Pancreatic (PHASE1, PHASE2)
- Phase I Study of APX005M in Pediatric Central Nervous System Tumors (PHASE1)
- Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (PHASE1)
- INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer (PHASE2)
- APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma (PHASE1, PHASE2)
- A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) (PHASE1)
- APX005M and Doxorubicin in Advanced Sarcoma (PHASE2)
- APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APX005M CI brief — competitive landscape report
- APX005M updates RSS · CI watch RSS
- Apexigen America, Inc. portfolio CI